Procter & Gamble Health Limited
NSE:PGHL.NS
5158.45 (INR) • At close September 16, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) INR.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 11,512.6 | 12,296.2 | 10,920.4 | 9,907.9 | 9,033.845 | 8,489.9 | 11,039.6 | 9,925.6 | 9,375.6 | 8,629 | 7,939.6 | 6,564.2 | 5,575.7 | 5,090.8 | 4,731.1 | 3,894.6 | 3,148.3 |
| Cost of Revenue
| 5,731.2 | 3,618.4 | 3,671.1 | 3,392.7 | 5,016.292 | 2,713.4 | 4,454.9 | 4,166.3 | 4,522.7 | 4,164.8 | 3,805.5 | 3,019.9 | 2,427.8 | 2,078.7 | 2,060.9 | 1,599.9 | 1,264.9 |
| Gross Profit
| 5,781.4 | 8,677.8 | 7,249.3 | 6,515.2 | 4,017.553 | 5,776.5 | 6,584.7 | 5,759.3 | 4,852.9 | 4,464.2 | 4,134.1 | 3,544.3 | 3,147.9 | 3,012.1 | 2,670.2 | 2,294.7 | 1,883.4 |
| Gross Profit Ratio
| 0.502 | 0.706 | 0.664 | 0.658 | 0.445 | 0.68 | 0.596 | 0.58 | 0.518 | 0.517 | 0.521 | 0.54 | 0.565 | 0.592 | 0.564 | 0.589 | 0.598 |
| Reseach & Development Expenses
| 0 | 57.1 | 65.5 | 39.3 | 57.267 | 20.5 | 29.5 | 154.6 | 121.1 | 110.4 | 86.2 | 50.1 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 1,481.7 | 233.2 | 474.3 | 728.343 | 298.9 | 437.7 | 382.5 | 291 | 311.5 | 315 | 267.3 | 0 | 0 | 0 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | 744.9 | 1,094.5 | 864.3 | 1,189.6 | 999.1 | 933.7 | 669.4 | 728.5 | 634.2 | 587.9 | 447.4 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 2,995.4 | 2,226.6 | 1,327.7 | 1,338.6 | 1,917.943 | 1,298 | 1,371.4 | 1,051.9 | 1,019.5 | 945.7 | 902.9 | 714.7 | 0 | 0 | 0 | 0 | 0 |
| Other Expenses
| 0 | 183.9 | 2,893.6 | 2,938.1 | -73.934 | -489.5 | -498.3 | -307.8 | 5.5 | 5.6 | 5.1 | -205.3 | 2,191.8 | 2,054.3 | 1,705.4 | 1,377.2 | 884.7 |
| Operating Expenses
| 2,995.4 | 5,719.3 | 4,286.8 | 4,316 | 2,049.144 | 3,998.2 | 4,725.7 | 4,515.4 | 4,212.8 | 3,998.6 | 3,454 | 2,362 | 2,191.8 | 2,054.3 | 1,705.4 | 1,377.2 | 884.7 |
| Operating Income
| 2,786 | 3,142.4 | 2,603.1 | 2,349.8 | 1,968.41 | 1,712.4 | 1,924.2 | 1,302.9 | 653 | 468.9 | 692.2 | 1,187 | 956.1 | 1,100.6 | 964.8 | 917.5 | 998.7 |
| Operating Income Ratio
| 0.242 | 0.256 | 0.238 | 0.237 | 0.218 | 0.202 | 0.174 | 0.131 | 0.07 | 0.054 | 0.087 | 0.181 | 0.171 | 0.216 | 0.204 | 0.236 | 0.317 |
| Total Other Income Expenses Net
| -52.8 | -0.4 | -69.4 | -17 | 397.269 | -132.6 | -402.3 | -200.7 | 180.3 | 196.7 | 190.3 | -19.1 | -0.2 | -143.5 | -0.3 | -0.1 | -0.1 |
| Income Before Tax
| 2,733.2 | 3,142 | 2,533.7 | 2,332.8 | 2,365.678 | 1,579.8 | 1,521.9 | 1,102.2 | 833.3 | 665.6 | 882.5 | 1,167.9 | 955.9 | 957.1 | 964.5 | 917.4 | 998.6 |
| Income Before Tax Ratio
| 0.237 | 0.256 | 0.232 | 0.235 | 0.262 | 0.186 | 0.138 | 0.111 | 0.089 | 0.077 | 0.111 | 0.178 | 0.171 | 0.188 | 0.204 | 0.236 | 0.317 |
| Income Tax Expense
| 723.4 | 847.3 | 608.5 | 564.8 | 671.803 | 562.5 | 582.8 | 343.3 | 297.7 | 233.4 | 323.7 | 383.9 | 319.1 | 325.3 | 309.7 | 287.3 | 310.4 |
| Net Income
| 2,009.8 | 2,294.7 | 1,925.2 | 1,768 | 1,693.875 | 8,387.2 | 939.1 | 758.9 | 535.6 | 432.2 | 558.8 | 784 | 636.8 | 631.8 | 654.8 | 630.1 | 688.2 |
| Net Income Ratio
| 0.175 | 0.187 | 0.176 | 0.178 | 0.188 | 0.988 | 0.085 | 0.076 | 0.057 | 0.05 | 0.07 | 0.119 | 0.114 | 0.124 | 0.138 | 0.162 | 0.219 |
| EPS
| 121.08 | 138.24 | 115.98 | 106.51 | 102.04 | 505.27 | 56.57 | 45.72 | 32.3 | 26 | 33.7 | 47.2 | 38.4 | 38.1 | 39 | 37.4 | 40.8 |
| EPS Diluted
| 121.08 | 138.24 | 115.98 | 106.51 | 102.04 | 505.27 | 56.57 | 45.72 | 32.3 | 26 | 33.7 | 47.2 | 38.4 | 38.1 | 39 | 37.4 | 40.8 |
| EBITDA
| 3,060 | 3,423.4 | 2,873.9 | 2,650.2 | 2,161.277 | 1,962.3 | 2,188.2 | 1,578.4 | 887.2 | 595.7 | 792.9 | 1,276 | 1,035.6 | 1,171.6 | 1,039.9 | 974.8 | 1,064.6 |
| EBITDA Ratio
| 0.266 | 0.278 | 0.263 | 0.267 | 0.239 | 0.231 | 0.198 | 0.159 | 0.095 | 0.069 | 0.1 | 0.194 | 0.186 | 0.23 | 0.22 | 0.25 | 0.338 |